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Abstract 
BACKGROUND: Scleromyxedema, also referred to as the Arndt-Gottron (S-AG) syndrome or the systemic form 
of Lichen myxedematosus (LM), is a cutaneous mucinosis with a chronic course and high lethality from systemic 
involvement of other organs and systems. Interesting in several aspects is the association between 
scleromyxedema and viral hepatitis about: 1) hepatitis virus infection as a possible etiological factor for the 
development of scleromyxedema, 2) antiretroviral therapy for the treatment of hepatitis as a method of reversing 
scleromyxedema and 3) antiviral drugs as inducers of scleromyxedema. 
CASE REPORT: We present a 53-year old patient who for nine months had been on tenofovir disoproxil 245 mg 
(0-0-1) therapy for chronic hepatitis B. Three months after the start of antiviral therapy (i.e. for a period of 6 
months), the patient observed swelling, itching and hardening of the skin on the face, ears and hands, which 
subsequently spread throughout the trunk. Subsequent histological study of a skin biopsy revealed changes of 
scleromyxedema at an advanced stage, though immunoelectrophoresis of serum and urine excluded the 
presence of paraproteinaemia or para proteinuria. Systemic antihistamine and topical corticosteroid therapy were 
instituted. Bone involvement with possible plasmacytoma was excluded, and a myelogram showed evidence of an 
erythroblastic reaction of bone marrow. 
CONCLUSION: We believe that drug-induced scleromyxedema is a rare but possible phenomenon. We describe 
the first case of tenofovir-induced scleromyxedema within the framework of chronic hepatitis B treatment. 
 
 
 
 
 
 
 
 
Introduction 
 
Scleromyxedema, a systemic form of lichen 
myxedematosus (LM) [1], is associated with 
significant mortality [2], [3], [4]. Interesting in this 
regard is the association of scleromyxedema with 
hepatitis virus [5]. Scleromyxedema may occur 
secondarily in patients with viral hepatitis C [5], [6]. 
According to some authors, antiviral therapy for the 
treatment of hepatitis leads to the reversal of 
scleromyxedema and, according to others, treatment 
with interferon alpha 2 leads to worsening of LM [7]. 
We describe a patient in whom we believe there is a 
possible association between the development of 
scleromyxedema and the use of tenofovir disoproxil 
for hepatitis B. 
 
 
Case report 
 
We present a 53-year-old man with type 2 
diabetes mellitus, chronic hepatitis B, hepatic 
cirrhosis, duodenal ulcer, mild splenomegaly, chronic 
cholecystitis and hepatitis B associated nephropathy. 
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The patient was receiving treatment with insulin 
degludec 30 IU-0 -0 and insulin aspart 10 IU-14 IU-14 
IU, and for the past nine months, he received tenofovir 
disoproxil 245 mg (0-0-1) for treatment of chronic 
hepatitis B. The patient was hospitalized for swelling, 
pruritus and hardening of the skin on the face, ears 
and hands, which subsequently spread to involve the 
trunk. Skin complaints began 3 months after the start 
of therapy with tenofovir. Dermatological examination 
revealed significant thickening and hardening in the 
areas of the face, neck, body and extremities, and 
generalised lichenoid papules were also found (Figure 
1a, 1b, 1c, and 1d).  
 
Figure 1: a) Hardening of the face skin; b) Skin-colored small 
papules on the ear skin; c) Hardening of the skin on the back and 
neck; d) Multiple disseminated papules on the skin of the hands and 
arthropathy 
 
Based on clinical data, scleromyxedema, 
scleredema of Buschke and lichen amyloidosis were 
considered as possible diagnoses. A skin biopsy 
showed numerous fibroblasts and irregularly arranged 
collagen bundles with prominent mucin deposition 
(Figure 2), consistent with an advanced stage of 
scleromyxedema.  
Double antihistamine therapy was initiated 
due to the presence of severe itching, and 
flumetasone pivalate/clioquinol was administered 
topically. The consultation was obtained from a 
gastroenterologist, who concluded that, given the 
patient’s ongoing chronic hepatitis B and posthepatic 
cirrhosis, it would not be appropriate to start systemic 
corticosteroid therapy because of its 
immunosuppressive effect. Immunoelectrophoresis of 
serum and urine excluded paraproteinaemia or para 
proteinuria. During the hospitalisation, additional tests 
were performed. Skull and pelvic radiography 
excluded possible bone involvement with 
plasmacytoma, and ultrasound of the abdominal 
organs showed no paraneoplastic process. 
 
Figure 2: а) This skin biopsy shows a combination of numerous 
fibroblasts, mucin, and irregularly arranged collagen bundles; b) At 
higher magnification, there are irregularly arranged collagen and 
scattered spindled cells, representing fibroblasts, within a mucinous 
background; с) This image shows details of fibroblasts around the 
cross-sectional profile of an eccrine sweat duct 
 
Laboratory data included CEA - 2.87 μg/ml (0-
5), PSA-0.178 μg/ml (0-3,100), and AST-31 IU (0-
200). A myelogram showed evidence of an 
erythroblastic reaction of bone marrow, a mild 
leukemoid reaction of granulocyte-neutrophil type, and 
a mild eosinophilic bone marrow response-consistent 
with reactive changes. The patient was referred to the 
haematology and oncology clinic for bone marrow 
puncture, bone scintigraphy, and further therapeutic 
recommendations. Аmbulatory systemic therapy with 
Azathioprine 2 x 50 mg/day and topical-flumethasone 
pivalate/clioquinol was initiated. After a few months of 
treatment with Azathioprine 2 x 50 mg/day, a slight 
improvement in major symptoms was observed. It is 
planned to discontinue tenofovir therapy after 
consultation with a gastroenterologist. The viral load 
following azathioprine therapy was 0, but the therapy 
was stopped and after a 1-week treatment with 
intravenous immunoglobulin will be initiated. 
Treatment with intravenous IgG will be performed as 
follows: 2 g per kg/every month, divided into five days 
with 430 mg/day for 6 months. 
 
 
Discussion 
 
Scleromyxedema or Arndt-Gottron (S-AG) 
syndrome is a cutaneous mucinosis that mainly 
affects adults between 30 and 70 years of age and 
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whose aetiology is not fully understood [2]. The 
disease is defined as a systemic form of Lichen 
myxedematosus [5]. It is believed that in 80% of 
patients there is monoclonal gammopathy and there is 
probably an immune response of B-cells to antigenic 
mucin deposits in the dermis [3]. However, it is 
possible to observe scleromyxedema without 
underlying paraproteinemia, as in our patient [3]. A 
major sign of this disease is the histopathological triad 
of dermal mucin deposition, fibroblast proliferation, 
and fibrosis [2]. The clinical condition is characterised 
by widespread lichenoid papules which coalesce to 
form generalised plaques that cause extensive 
thickening and hardening of the skin [2], [3]. There 
may also be an atypical clinical presentation with 
cutaneous and subcutaneous nodules [8]. According 
to prevailing literature, the absence of thyroid disease 
should also be considered as one of the main criteria 
for the diagnosis of scleromyxedema [1]. 
Scleromyxedema is a chronic disease that 
may be accompanied by severe systemic 
manifestations such as gastrointestinal, neurological, 
cardiac, muscular, renal, pulmonary, or 
ophthalmological disorders, and these associations 
may cause significant disability and may be fatal [3], 
[4]. 
A rare variant that can be associated with a 
high risk of mortality is the so-called 'dermato-neuro 
syndrome' [9]. It is characterised by a prodromal flu-
like period, followed by fever, convulsions and coma 
[9].  
Of interest are the rare cases, such as this 
one, in which scleromyxedema is present within the 
framework of a hepatitis virus infection [5]. Much of 
the literature on this association describes 
scleromyxedema secondary to hepatitis C virus and 
successful treatment with antiviral therapy [5], [6]. 
According to these sources, hepatitis C infection 
should be considered as a possible etiological factor 
for the development of scleromyxedema [5], [6]. 
However, it is also possible that lichen 
myxedematosus may worsen in the setting of chronic 
hepatitis C therapy treated with interferon alfa-2a [7]. 
Also, there is a reported case of scleromyxedema 
development as a result of interferon beta-1a (IFN 
beta-1a) therapy following a diagnosis of multiple 
sclerosis (MS) [10]. At present, the mechanism by 
which IFN beta-1a may lead to the development of 
scleromyxedema has not been established [10]. In 
any event, we believe that the possibility of drug-
induced scleromyxedema is worthy of serious 
consideration. 
 Also described in the literature is a case of 
papular mucinosis (PM) in association with HIV 
infection in a patient with highly active antiretroviral 
therapy (HAART) with tenofovir 
disoproxil/emtricitabine and lopinavir/ritonavir [11]. 
According to studies: 1) antiretroviral therapy 
(including tenofovir) in patients with HIV infection and 
lichen myxedematosus leads to a complete resolution 
of papular mucinosis and 2) tenofovir prevents hepatic 
fibrosis development and protects against bleomycin-
induced dermal fibrosis by downregulating adenosine 
levels in the liver and skin [12], [13]. These data 
indicate that tenofovir, through a variety of 
mechanisms, may affect the pathogenetic chain of 
events leading to cutaneous mucinosis and fibrosis. 
Based on the previous data, we believe that we 
describe the first case of scleromyxedema induced by 
treatment with tenofovir for hepatitis B. 
 At the moment there is no specific definitive 
treatment of scleromyxedema [4]. There is a wide 
range of treatment options, such as high-dose 
corticosteroids, a variety of immunosuppressive and 
chemotherapeutic drugs, PUVA and UVA1 
phototherapy, interferon-α, retinoids, thalidomide, 
bortezomib, and autologous stem cell transplantation, 
but intravenous immunoglobulin (IVIg) treatment is 
considered to be relatively effective and safe 
treatment, and appears to be the treatment of choice 
for scleromyxedema [3], [4], [8]. Also, some authors 
suggest that treatment with intravenous 
immunoglobulins is considered and recommended as 
First Line therapy [14]. They recommend a dose of 2 g 
per kg, divided into four/five partial doses on four/five 
days, with the interval between cycles from 4 weeks to 
maximally 6 weeks (as well as the one assigned to 
our patient) [14]. 
In conclusion, the exact mechanisms under 
which antiviral drugs affect skin deposits of mucin and 
cutaneous fibrosis have not yet been established. 
There are contradictory data according to which, on 
the one hand, drug therapy for hepatitis C worsens 
LM, and on the other, treatment with tenofovir in HIV-
infected patients leads to a reversal of cutaneous 
mucinosis. However, they indicate that the 
pathogenesis of scleromyxedema may be associated 
with different drug groups. We believe that we are 
presenting the first case of tenofovir-induced 
scleromyxedema. 
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